Exosome targeted therapy—a step in the future

World-wide 265,000 people are diagnosed with pancreatic cancer each year, of which 74% will die within 1 year. Most pancreatic adenocarcinomas (PDACs) are diagnosed at an advanced stage with 91% of the patients with regional metastatic disease (1). As a result, PDAC has one of the worst prognoses among all cancers with a 5-year survival of less than 5%. It is one of the few cancers still increasing in incidence and by 2030, if current trends continue and without the discovery of effective treatments, PDAC will be the second leading cause of cancer death in the US (2).